New hope for aggressive colon cancer: targeted drug AK104 tested before surgery
NCT ID NCT07412613
First seen Feb 18, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This study tests a new drug called AK104 (Cadonilimab) given before and after surgery for people with a specific type of colon cancer (MSI-H/dMMR) that can be removed. The goal is to see if AK104 works better than standard chemotherapy at shrinking the tumor and preventing the cancer from coming back. About 386 adults aged 18-75 with stage IIB-III colon cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.